Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 9/20 | 0.47 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.46 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
| ▸ | PRKACB | P22694 | 1/20 | 0.35 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18586078 | 0.81 | RPS6KA5 (0.68) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL30556253 | 0.81 | RPS6KA5 (0.67) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL19100350 | 0.81 | RPS6KA5 (0.67) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL5090434 | 0.78 | RPS6KA5 (0.68) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL30886751 | 0.78 | RPS6KA5 (0.52) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL20357808 | 0.78 | RPS6KA5 (0.47) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL20357868 | 0.78 | RPS6KA5 (0.47) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL17373179 | 0.76 | RPS6KA5 (0.43) | RPS6KA5RPS6KA4BIRC5CDK2MAPK8 | |
| SCHEMBL28612234 | 0.75 | RPS6KA5 (0.46) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 | |
| SCHEMBL28617905 | 0.75 | RPS6KA5 (0.47) | RPS6KA5RPS6KA4BIRC5CDK2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345900-B1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | BEBETTER MED INC (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | BEBETTER MED INC. (CN) | 2022-03-08 | — | — | US | disclosed |
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3345900-A1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Guangzhou Bebetter Medicine Technology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| CN-106117185-B | 2,4 2 nitrogen-containing group substituted uracil compounds and its preparation method and application | 广州必贝特医药技术有限公司 | 2017-11-07 | — | — | CN | disclosed |
| WO-2017036263-A1 | 2, 4-DI-(NITROGEN CONTAINING GROUP) SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | 广州科擎新药开发有限公司 | 2017-03-09 | — | — | WO | disclosed |
| CN-106117185-A | 2,4 2 nitrogen-containing group substituted pyrimidines compounds and its preparation method and application | 广州科擎新药开发有限公司 | 2016-11-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331891-A9 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | RPS6KA5 559/4885RPS6KA4 972/4885BIRC5 4089/4885 |
| US-20200165227-A1 | 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, KRAS | RPS6KA5 559/4885RPS6KA4 972/4885BIRC5 4089/4885 |
| US-11267802-B2 | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | EGFR, ERBB2, KRAS | RPS6KA5 559/4885RPS6KA4 972/4885BIRC5 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.